NEW YORK,, Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Equillium, Inc. ("Equillium" or the "Company") (NASDAQ: EQ), in connection with its takeover of Metacrine, Inc. (Metacrine) (NASDAQ: MTCR). Under the terms of the merger agreement, Equillium will issue stock valued at a 25% premium over the Metacrine net cash delivered at closing, which is estimated to be approximately $26 million.
Read more at prnewswire.comSHAREHOLDER ALERT: Weiss Law Investigates Equillium, Inc.
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
